Why Is Healthcare Technology Company Aclarion Stock Rocketing Premarket On Monday?

Benzinga

03-03

Aclarion, Inc. (NASDAQ:ACON) shares are trading higher premarket on Monday after the company disclosed a commercial partnership with Scripps Health in San Diego, CA.

This agreement will introduce Nociscan to Southern California and to the top spine specialists at Scripps Green and Scripps Health.

Notably, Scripps Health is a nonprofit healthcare system that operates five hospitals and 19 outpatient facilities, serving half a million patients annually with the support of 2,600 affiliated physicians.

Ryan Bond, Chief Strategy Officer of Aclarion. “We are pleased to bring Nociscan to Scripps Health and the millions of people throughout Southern California. Dr. Eastlack and his colleagues will now be able to utilize Nociscan in clinic and within on-going research trials, both of which are vitally important to their mission of advancing spine care.”

Last month, the company announced it secured funding for its CLARITY trial of its diagnostic tool, Nociscan.

Also, Aclarion identified Northwestern Medicine as the first site for the pivotal CLARITY trial, which aims to showcase Nociscan’s clinical and economic benefits in spine surgery.

Price Action: ACON shares are up 84.8% at $6.19 premarket at the last check Monday.

Read Next:

AST SpaceMobile Teams Up with Vodafone For Satellite Broadband Service Across Europe

Photo: One Photo via Shutterstock.

UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.

Get the latest stock analysis from Benzinga?

This article Why Is Healthcare Technology Company Aclarion Stock Rocketing Premarket On Monday? originally appeared on Benzinga.com

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2516633960"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2516633960\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2516633960?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-03 20:59","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2516633960","market":"us","top_or_hot":-1,"title":"Why Is Healthcare Technology Company Aclarion Stock Rocketing Premarket On Monday?","media":"Benzinga","content":"<html><body><img height=\"675\" src=\"https://s.yimg.com/uu/api/res/1.2/8yMqqat.rGuPppIIHo914Q--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/Benzinga/cc645613785c835512f5760837932ccc\" width=\"1200\"/>\n<p><strong><a href=\"https://laohu8.com/S/ACONU\">Aclarion, Inc.</a> </strong>(NASDAQ:ACON) shares are trading higher premarket on Monday after the company disclosed a commercial partnership with <strong>Scripps Health</strong> in San Diego, CA.</p>\n<p>This agreement will introduce Nociscan to Southern California and to the top spine specialists at Scripps Green and Scripps Health.</p>\n<p>Notably, Scripps Health is a nonprofit healthcare system that operates five hospitals and 19 outpatient facilities, serving half a million patients annually with the support of 2,600 affiliated physicians.</p>\n<p><strong>Ryan Bond</strong>, Chief <a href=\"https://laohu8.com/S/MSTR\">Strategy</a> Officer of Aclarion. “We are pleased to bring Nociscan to Scripps Health and the millions of people throughout Southern California. Dr. Eastlack and his colleagues will now be able to utilize Nociscan in clinic and within on-going research trials, both of which are vitally important to their mission of advancing spine care.”</p>\n<p>Last month, the company announced it secured funding for its CLARITY trial of its diagnostic tool, Nociscan.</p>\n<p>Also, Aclarion identified Northwestern Medicine as the first site for the pivotal CLARITY trial, which aims to showcase Nociscan’s clinical and economic benefits in spine surgery.</p>\n<p><strong>Price Action</strong>: ACON shares are up 84.8% at $6.19 premarket at the last check Monday.</p>\n<p><strong>Read Next:</strong></p>\n<ul>\n<li><strong>AST SpaceMobile Teams Up with Vodafone For Satellite Broadband Service Across Europe</strong></li>\n</ul>\n<p><em>Photo: One Photo via Shutterstock.</em></p>\n<p>UNLOCKED: 5 NEW TRADES EVERY WEEK. <strong>Click now to get top trade ideas daily</strong>, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.</p>\n<p>Get the latest stock analysis from Benzinga?</p>\n<ul></ul>\n<p>This article Why Is Healthcare Technology Company Aclarion Stock Rocketing Premarket On Monday? originally appeared on Benzinga.com</p>\n<p><i>© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.</i></p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is Healthcare Technology Company Aclarion Stock Rocketing Premarket On Monday?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is Healthcare Technology Company Aclarion Stock Rocketing Premarket On Monday?\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Benzinga</strong><span class=\"h-time small\">2025-03-03 20:59</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><img height=\"675\" src=\"https://s.yimg.com/uu/api/res/1.2/8yMqqat.rGuPppIIHo914Q--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/Benzinga/cc645613785c835512f5760837932ccc\" width=\"1200\"/>\n<p><strong><a href=\"https://laohu8.com/S/ACONU\">Aclarion, Inc.</a> </strong>(NASDAQ:ACON) shares are trading higher premarket on Monday after the company disclosed a commercial partnership with <strong>Scripps Health</strong> in San Diego, CA.</p>\n<p>This agreement will introduce Nociscan to Southern California and to the top spine specialists at Scripps Green and Scripps Health.</p>\n<p>Notably, Scripps Health is a nonprofit healthcare system that operates five hospitals and 19 outpatient facilities, serving half a million patients annually with the support of 2,600 affiliated physicians.</p>\n<p><strong>Ryan Bond</strong>, Chief <a href=\"https://laohu8.com/S/MSTR\">Strategy</a> Officer of Aclarion. “We are pleased to bring Nociscan to Scripps Health and the millions of people throughout Southern California. Dr. Eastlack and his colleagues will now be able to utilize Nociscan in clinic and within on-going research trials, both of which are vitally important to their mission of advancing spine care.”</p>\n<p>Last month, the company announced it secured funding for its CLARITY trial of its diagnostic tool, Nociscan.</p>\n<p>Also, Aclarion identified Northwestern Medicine as the first site for the pivotal CLARITY trial, which aims to showcase Nociscan’s clinical and economic benefits in spine surgery.</p>\n<p><strong>Price Action</strong>: ACON shares are up 84.8% at $6.19 premarket at the last check Monday.</p>\n<p><strong>Read Next:</strong></p>\n<ul>\n<li><strong>AST SpaceMobile Teams Up with Vodafone For Satellite Broadband Service Across Europe</strong></li>\n</ul>\n<p><em>Photo: One Photo via Shutterstock.</em></p>\n<p>UNLOCKED: 5 NEW TRADES EVERY WEEK. <strong>Click now to get top trade ideas daily</strong>, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.</p>\n<p>Get the latest stock analysis from Benzinga?</p>\n<ul></ul>\n<p>This article Why Is Healthcare Technology Company Aclarion Stock Rocketing Premarket On Monday? originally appeared on Benzinga.com</p>\n<p><i>© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.</i></p></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.yahoo.com/news/why-healthcare-technology-company-aclarion-125952910.html\">Benzinga</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ACON","symbol_name":"ACLARION, INC","start_time":0,"source_url":"https://finance.yahoo.com/news/why-healthcare-technology-company-aclarion-125952910.html","article_id":"2516633960","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2516633960","pubTimestamp":1741006792,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Aclarion, Inc.  shares are trading higher premarket on Monday after the company disclosed a commercial partnership with Scripps Health in San Diego, CA.This agreement will introduce Nociscan to Southern California and to the top spine specialists at Scripps Green and Scripps Health.Notably, Scripps Health is a nonprofit healthcare system that operates five hospitals and 19 outpatient facilities, serving half a million patients annually with the support of 2,600 affiliated physicians.Ryan Bond, Chief Strategy Officer of Aclarion. “We are pleased to bring Nociscan to Scripps Health and the millions of people throughout Southern California. Dr. Eastlack and his colleagues will now be able to utilize Nociscan in clinic and within on-going research trials, both of which are vitally important to their mission of advancing spine care.”Last month, the company announced it secured funding for its CLARITY trial of itsdiagnostic tool, Nociscan.Also, Aclarion identified Northwestern Medicine as th","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ACON":"ACLARION, INC","HCSG":"Healthcare Svcs Group Inc","ACONW":"Aclarion Equity Warrant Exp 1st Dec 2026 Warrant","BK4167":"医疗保健技术","BK4137":"综合支持服务"},"translate_title":"为什么医疗保健技术公司Aclarion股价周一盘前飙升？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACON":1,"ACONW":0.9,"HCSG":1},"content_text":"Aclarion, Inc. (NASDAQ:ACON) shares are trading higher premarket on Monday after the company disclosed a commercial partnership with Scripps Health in San Diego, CA.\nThis agreement will introduce Nociscan to Southern California and to the top spine specialists at Scripps Green and Scripps Health.\nNotably, Scripps Health is a nonprofit healthcare system that operates five hospitals and 19 outpatient facilities, serving half a million patients annually with the support of 2,600 affiliated physicians.\nRyan Bond, Chief Strategy Officer of Aclarion. “We are pleased to bring Nociscan to Scripps Health and the millions of people throughout Southern California. Dr. Eastlack and his colleagues will now be able to utilize Nociscan in clinic and within on-going research trials, both of which are vitally important to their mission of advancing spine care.”\nLast month, the company announced it secured funding for its CLARITY trial of its diagnostic tool, Nociscan.\nAlso, Aclarion identified Northwestern Medicine as the first site for the pivotal CLARITY trial, which aims to showcase Nociscan’s clinical and economic benefits in spine surgery.\nPrice Action: ACON shares are up 84.8% at $6.19 premarket at the last check Monday.\nRead Next:\n\nAST SpaceMobile Teams Up with Vodafone For Satellite Broadband Service Across Europe\n\nPhoto: One Photo via Shutterstock.\nUNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.\nGet the latest stock analysis from Benzinga?\n\nThis article Why Is Healthcare Technology Company Aclarion Stock Rocketing Premarket On Monday? originally appeared on Benzinga.com\n© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}